Anatomy of the cervicomental region: Insights from an anatomy laboratory and roundtable discussion

Jeffrey M. Kenkel, Derek H. Jones, Steven Fagien, Dee Anna Glaser, Gary D. Monheit, Karen Stauffer, Jonathan M. Sykes

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

In 2015, ATX-101 (deoxycholic acid injection; Kybella in the United States and Belkyra in Canada; Kythera Biopharmaceuticals, Inc., Westlake Village, CA [an affiliate of Allergan plc, Dublin, Ireland]) was approved as a first-inclass injectable drug for reduction of submental fat. Use of a pharmacologic/injectable therapy within the submental region requires a thorough understanding of cervicomental anatomy to ensure proper injection technique and safe administration. To this end, an anatomy laboratory was conducted to review key external landmarks and important internal anatomic structures that characterize the lower face and anterior neck. External landmarks that define the boundaries of the cervicomental and submental regions were identified including the inferior mandibular border, the anterior border of the sternocleidomastoid muscle, the antegonial notch, the submental crease, the thyroid notch, and the hyoid bone. Relevant internal anatomic structures, including preplatysmal submental fat (the target tissue for ATX-101) and the platysma muscle as well as critical neurovascular and glandular tissues were revealed by dissection. Of particular interest was the marginal mandibular branch of the facial nerve because it typically courses along the inferior mandibular border near the proposed treatment area for ATX-101.

Original languageEnglish (US)
Pages (from-to)S282-S287
JournalDermatologic Surgery
Volume42
DOIs
StatePublished - 2016

Fingerprint

Anatomy
Injections
Fats
Hyoid Bone
Deoxycholic Acid
Facial Nerve
Ireland
Canada
Dissection
Thyroid Gland
Neck
Muscles
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Surgery
  • Dermatology

Cite this

Anatomy of the cervicomental region : Insights from an anatomy laboratory and roundtable discussion. / Kenkel, Jeffrey M.; Jones, Derek H.; Fagien, Steven; Glaser, Dee Anna; Monheit, Gary D.; Stauffer, Karen; Sykes, Jonathan M.

In: Dermatologic Surgery, Vol. 42, 2016, p. S282-S287.

Research output: Contribution to journalArticle

Kenkel, Jeffrey M. ; Jones, Derek H. ; Fagien, Steven ; Glaser, Dee Anna ; Monheit, Gary D. ; Stauffer, Karen ; Sykes, Jonathan M. / Anatomy of the cervicomental region : Insights from an anatomy laboratory and roundtable discussion. In: Dermatologic Surgery. 2016 ; Vol. 42. pp. S282-S287.
@article{f5123ae15b684e0390d828434cecf450,
title = "Anatomy of the cervicomental region: Insights from an anatomy laboratory and roundtable discussion",
abstract = "In 2015, ATX-101 (deoxycholic acid injection; Kybella in the United States and Belkyra in Canada; Kythera Biopharmaceuticals, Inc., Westlake Village, CA [an affiliate of Allergan plc, Dublin, Ireland]) was approved as a first-inclass injectable drug for reduction of submental fat. Use of a pharmacologic/injectable therapy within the submental region requires a thorough understanding of cervicomental anatomy to ensure proper injection technique and safe administration. To this end, an anatomy laboratory was conducted to review key external landmarks and important internal anatomic structures that characterize the lower face and anterior neck. External landmarks that define the boundaries of the cervicomental and submental regions were identified including the inferior mandibular border, the anterior border of the sternocleidomastoid muscle, the antegonial notch, the submental crease, the thyroid notch, and the hyoid bone. Relevant internal anatomic structures, including preplatysmal submental fat (the target tissue for ATX-101) and the platysma muscle as well as critical neurovascular and glandular tissues were revealed by dissection. Of particular interest was the marginal mandibular branch of the facial nerve because it typically courses along the inferior mandibular border near the proposed treatment area for ATX-101.",
author = "Kenkel, {Jeffrey M.} and Jones, {Derek H.} and Steven Fagien and Glaser, {Dee Anna} and Monheit, {Gary D.} and Karen Stauffer and Sykes, {Jonathan M.}",
year = "2016",
doi = "10.1097/DSS.0000000000000896",
language = "English (US)",
volume = "42",
pages = "S282--S287",
journal = "Dermatologic Surgery",
issn = "1076-0512",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Anatomy of the cervicomental region

T2 - Insights from an anatomy laboratory and roundtable discussion

AU - Kenkel, Jeffrey M.

AU - Jones, Derek H.

AU - Fagien, Steven

AU - Glaser, Dee Anna

AU - Monheit, Gary D.

AU - Stauffer, Karen

AU - Sykes, Jonathan M.

PY - 2016

Y1 - 2016

N2 - In 2015, ATX-101 (deoxycholic acid injection; Kybella in the United States and Belkyra in Canada; Kythera Biopharmaceuticals, Inc., Westlake Village, CA [an affiliate of Allergan plc, Dublin, Ireland]) was approved as a first-inclass injectable drug for reduction of submental fat. Use of a pharmacologic/injectable therapy within the submental region requires a thorough understanding of cervicomental anatomy to ensure proper injection technique and safe administration. To this end, an anatomy laboratory was conducted to review key external landmarks and important internal anatomic structures that characterize the lower face and anterior neck. External landmarks that define the boundaries of the cervicomental and submental regions were identified including the inferior mandibular border, the anterior border of the sternocleidomastoid muscle, the antegonial notch, the submental crease, the thyroid notch, and the hyoid bone. Relevant internal anatomic structures, including preplatysmal submental fat (the target tissue for ATX-101) and the platysma muscle as well as critical neurovascular and glandular tissues were revealed by dissection. Of particular interest was the marginal mandibular branch of the facial nerve because it typically courses along the inferior mandibular border near the proposed treatment area for ATX-101.

AB - In 2015, ATX-101 (deoxycholic acid injection; Kybella in the United States and Belkyra in Canada; Kythera Biopharmaceuticals, Inc., Westlake Village, CA [an affiliate of Allergan plc, Dublin, Ireland]) was approved as a first-inclass injectable drug for reduction of submental fat. Use of a pharmacologic/injectable therapy within the submental region requires a thorough understanding of cervicomental anatomy to ensure proper injection technique and safe administration. To this end, an anatomy laboratory was conducted to review key external landmarks and important internal anatomic structures that characterize the lower face and anterior neck. External landmarks that define the boundaries of the cervicomental and submental regions were identified including the inferior mandibular border, the anterior border of the sternocleidomastoid muscle, the antegonial notch, the submental crease, the thyroid notch, and the hyoid bone. Relevant internal anatomic structures, including preplatysmal submental fat (the target tissue for ATX-101) and the platysma muscle as well as critical neurovascular and glandular tissues were revealed by dissection. Of particular interest was the marginal mandibular branch of the facial nerve because it typically courses along the inferior mandibular border near the proposed treatment area for ATX-101.

UR - http://www.scopus.com/inward/record.url?scp=85014883431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014883431&partnerID=8YFLogxK

U2 - 10.1097/DSS.0000000000000896

DO - 10.1097/DSS.0000000000000896

M3 - Article

C2 - 27787268

AN - SCOPUS:85014883431

VL - 42

SP - S282-S287

JO - Dermatologic Surgery

JF - Dermatologic Surgery

SN - 1076-0512

ER -